Kevin M. Klifto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin M. Klifto has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Charles Scott Hultman
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
6 shared publications - Christopher S. Klifto
Division of Hand Surgery, Department of Orthopaedics, Duke University Schol of Medicine, 40 Duke Medicine Circlel̥, Durham, NC 27710, USA
4 shared publications - Stella M. Seal
Welch Medical Library, Johns Hopkins University School of Medicine, Baltimore, USA
4 shared publications - Arnold Lee Dellon
Johns Hopkins University
3 shared publications Caresse F. Gurno
Department of Neurosurgery, The Johns Hopkins Hospital, Baltimore, MD, USA
3 shared publicationsChristopher S. Klifto
3 shared publications
Latest Publications
- 7 September 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (5) , 1406-1414
High‐Resolution Ultrasound for Diagnosing Severity of Traumatic Peripheral Nerve Injuries‐in‐Continuity: A Systematic Review, Meta‐Analysis of Individual Participants' Data, and Illustrative Patient Series
Introduction/Aims: High‐resolution ultrasound (HRUS) may help evaluate traumatic peripheral nerve injuries (PNIs), but the sonographic features that distinguish low‐ from high‐grade injury remain poorly defined. This study evaluated the utility of HRUS for differentiating injury severity by synthesizing data from the literature and applying these findings to an illustrative institutional patient series. Methods: We queried for studies reporting HRUS findings in iatrogenic/traumatic PNI resulting in neurapraxia or axonotmesis. Individual participant data (IPD) were extracted and synthesized. Meta‐analysis was performed via a 1‐stage IPD approach to estimate associations between HRUS findings and injury grade. Findings from the review were then applied to an illustrative institutional series of five patients who underwent HRUS during initial clinical evaluation. Results: The systematic review included 74 patients from 24 studies. Focal nerve enlargement, hypoechoic nerve perimeter, and disruption of fascicular echotexture were observed in 82.4%, 63.5%, and 45.9% of patients, respectively. Fascicular echotexture disruption was present in 73.8% of high‐grade injuries compared to 9.4% of low‐grade injuries. Meta‐analysis revealed fascicular echotexture disruption was independently associated with high‐grade injury (aOR = 21.6; 95% CI [4.02–116], p = 0.002). Patient series findings were similar; one patient had preserved fascicular architecture and recovered under conservative management (low‐grade PNI), while four patients had disrupted fascicular echotexture and were confirmed intraoperatively to have high‐grade axonotmesis. Discussion: Traumatic PNIs demonstrated categorizable HRUS findings that may serve as a useful adjunct in multimodal assessment of injury severity. Disruption of fascicular echotexture appeared most associated with high‐grade lesions‐in‐continuity, although prospective validation with standardized imaging protocols is needed.
- 7 September 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (5) , 1406-1414
High‐Resolution Ultrasound for Diagnosing Severity of Traumatic Peripheral Nerve Injuries‐in‐Continuity: A Systematic Review, Meta‐Analysis of Individual Participants' Data, and Illustrative Patient Series
Introduction/Aims: High‐resolution ultrasound (HRUS) may help evaluate traumatic peripheral nerve injuries (PNIs), but the sonographic features that distinguish low‐ from high‐grade injury remain poorly defined. This study evaluated the utility of HRUS for differentiating injury severity by synthesizing data from the literature and applying these findings to an illustrative institutional patient series. Methods: We queried for studies reporting HRUS findings in iatrogenic/traumatic PNI resulting in neurapraxia or axonotmesis. Individual participant data (IPD) were extracted and synthesized. Meta‐analysis was performed via a 1‐stage IPD approach to estimate associations between HRUS findings and injury grade. Findings from the review were then applied to an illustrative institutional series of five patients who underwent HRUS during initial clinical evaluation. Results: The systematic review included 74 patients from 24 studies. Focal nerve enlargement, hypoechoic nerve perimeter, and disruption of fascicular echotexture were observed in 82.4%, 63.5%, and 45.9% of patients, respectively. Fascicular echotexture disruption was present in 73.8% of high‐grade injuries compared to 9.4% of low‐grade injuries. Meta‐analysis revealed fascicular echotexture disruption was independently associated with high‐grade injury (aOR = 21.6; 95% CI [4.02–116], p = 0.002). Patient series findings were similar; one patient had preserved fascicular architecture and recovered under conservative management (low‐grade PNI), while four patients had disrupted fascicular echotexture and were confirmed intraoperatively to have high‐grade axonotmesis. Discussion: Traumatic PNIs demonstrated categorizable HRUS findings that may serve as a useful adjunct in multimodal assessment of injury severity. Disruption of fascicular echotexture appeared most associated with high‐grade lesions‐in‐continuity, although prospective validation with standardized imaging protocols is needed.
- Open Access
- 22 August 2026
- Published by Elsevier in JPRAS Open
- Vol. 52, 244-252
Unmasked neuropathic groin pain: risk of reoperation
- 22 August 2026
- Published by Elsevier in JPRAS Open
- Vol. 52, 244-252
Open AccessUnmasked neuropathic groin pain: risk of reoperation
- 2 August 2026
- Published by Elsevier in Surgical Oncology
- Vol. 68
Clinical predictors of pain 24 Months after intraoperative intercostal nerve Cryoanalgesia for anatomical lung resection
- 2 August 2026
- Published by Elsevier in Surgical Oncology
- Vol. 68
Clinical predictors of pain 24 Months after intraoperative intercostal nerve Cryoanalgesia for anatomical lung resection
- 15 August 2025
- Published by Wolters Kluwer Health in Journal of the American Academy of Orthopaedic Surgeons
- Vol. 34 (4) , e536-e554
Evidence for Systemic Perioperative Antibiotic Prophylaxis for Prevention of Fracture-related Infections Following Open Fractures: Systematic Review and Meta-Analysis of Randomized, Controlled, Clinical Trials
Introduction: Clinical guidelines rely heavily on expert opinions and institution protocols to provide recommendations for administration of systemic antibiotic prophylaxis for open extremity fractures to prevent fracture-related infections. The purpose of this study was to determine evidence-based (1) durations; (2) types; (3) dosing regimens of systemic perioperative antibiotic prophylaxis following Gustilo-Anderson types I, I/II, II, III, and I/II/III, for upper and lower extremity open fractures, isolated upper extremity open fractures, and isolated lower extremity open fractures to prevent fracture-related infections. Methods: Guidelines from Preferred Reporting Items for Systematic Reviews and Meta-Analysis, Cochrane, and the GRADE approach were implemented to structure and synthesize this study. Five databases (PubMed, Cochrane Library, Web of Science, Scopus, CINAHL) were systematically and independently searched for randomized controlled trials (RCTs) meeting eligibility criteria. Included patients had open extremity fractures and were treated with prophylactic systemic antibiotics administered perioperatively (preoperative, intraoperative, postoperative). Meta-analyses were done of the data. Results: Twenty-one (n = 21) RCTs met eligibility criteria (Gustilo-Anderson type I = 6, Gustilo-Anderson type II = 4, Gustilo-Anderson type I/II = 12, Gustilo-Anderson type III = 4, Gustilo-Anderson type I/II/III = 21). Summary tables were generated to provide evidence-based durations and types of systemic antibiotic prophylaxis after Gustilo-Anderson types I, I/II, II, III, and I/II/III, for upper and lower extremity open fractures, isolated upper extremity (hand) open fractures, and isolated lower extremity open fractures. Discussion: Although data were derived primarily from older studies, we summarized the strongest available evidence from RCTs for antibiotic prophylaxis following Gustilo-Anderson types I, I/II, II, III, and I/II/III, for upper and lower extremity open fractures, isolated upper extremity open fractures, and isolated lower extremity open fractures.
- 15 August 2025
- Published by Wolters Kluwer Health in Journal of the American Academy of Orthopaedic Surgeons
- Vol. 34 (4) , e536-e554
Evidence for Systemic Perioperative Antibiotic Prophylaxis for Prevention of Fracture-related Infections Following Open Fractures: Systematic Review and Meta-Analysis of Randomized, Controlled, Clinical Trials
Introduction: Clinical guidelines rely heavily on expert opinions and institution protocols to provide recommendations for administration of systemic antibiotic prophylaxis for open extremity fractures to prevent fracture-related infections. The purpose of this study was to determine evidence-based (1) durations; (2) types; (3) dosing regimens of systemic perioperative antibiotic prophylaxis following Gustilo-Anderson types I, I/II, II, III, and I/II/III, for upper and lower extremity open fractures, isolated upper extremity open fractures, and isolated lower extremity open fractures to prevent fracture-related infections. Methods: Guidelines from Preferred Reporting Items for Systematic Reviews and Meta-Analysis, Cochrane, and the GRADE approach were implemented to structure and synthesize this study. Five databases (PubMed, Cochrane Library, Web of Science, Scopus, CINAHL) were systematically and independently searched for randomized controlled trials (RCTs) meeting eligibility criteria. Included patients had open extremity fractures and were treated with prophylactic systemic antibiotics administered perioperatively (preoperative, intraoperative, postoperative). Meta-analyses were done of the data. Results: Twenty-one (n = 21) RCTs met eligibility criteria (Gustilo-Anderson type I = 6, Gustilo-Anderson type II = 4, Gustilo-Anderson type I/II = 12, Gustilo-Anderson type III = 4, Gustilo-Anderson type I/II/III = 21). Summary tables were generated to provide evidence-based durations and types of systemic antibiotic prophylaxis after Gustilo-Anderson types I, I/II, II, III, and I/II/III, for upper and lower extremity open fractures, isolated upper extremity (hand) open fractures, and isolated lower extremity open fractures. Discussion: Although data were derived primarily from older studies, we summarized the strongest available evidence from RCTs for antibiotic prophylaxis following Gustilo-Anderson types I, I/II, II, III, and I/II/III, for upper and lower extremity open fractures, isolated upper extremity open fractures, and isolated lower extremity open fractures.
- 2 February 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 90, 292-304
Tumescent technique for split-thickness skin graft donor sites: A systematic review of randomized controlled trials
- 2 February 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 90, 292-304
Tumescent technique for split-thickness skin graft donor sites: A systematic review of randomized controlled trials
- 29 November 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 152 (6) , 1376-1377
Pharmacotherapeutics in Plastic and Reconstructive Surgery
- 29 November 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 152 (6) , 1376-1377
Pharmacotherapeutics in Plastic and Reconstructive Surgery
- 11 September 2022
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 35, 102018
Time to publication for orthopaedic surgery peer-reviewed journals: A cross-sectional bibliometric analysis
- 11 September 2022
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 35, 102018
Time to publication for orthopaedic surgery peer-reviewed journals: A cross-sectional bibliometric analysis
- 22 May 2022
- Published by SAGE Publications in HAND
- Vol. 19 (1) , 113-127
Platelet-Rich Plasma Versus Corticosteroid Injections for the Treatment of Mild-to-Moderate Carpal Tunnel Syndrome: A Markov Cost-Effectiveness Decision Analysis
Background: Platelet-rich plasma (PRP) or corticosteroid injections may be used to conservatively treat mild-to-moderate carpal tunnel syndrome (CTS). We evaluated the cost-effectiveness of PRP injections versus corticosteroid injections for the treatment of mild-to-moderate CTS. Methods: Markov modeling was used to analyze the base-case 45-year-old patient with mild-to-moderate CTS, unresponsive to conservative treatments, never previously treated with an injection or surgery, treated with a single injection of PRP, or methylprednisolone/triamcinolone 40 mg/mL. Transition probabilities were derived from level-I/II studies, utility values from the Tufts University Cost-Effectiveness Analysis Registry reported using visual analog scale (VAS), Boston Carpal Tunnel Questionnaire Symptom severity (BCTQ-S), and Boston Carpal Tunnel Questionnaire Functional status (BCTQ-F), and costs from Medicare, published studies, and industry. Analyses were performed from healthcare/societal perspectives. Outcomes were incremental cost-effectiveness ratios (ICER) and net monetary benefits (NMB). Willingness-to-pay thresholds were $50 000 and $100 000. Deterministic/probabilistic sensitivity analyses were performed. Results: From a healthcare perspective, compared to PRP injections, the ICER for corticosteroid injections measured by VAS: -$13.52/quality-adjusted-life-years (QALY), BCTQ-S: -$11.88/QALY, and BCTQ-F: -$16.04/QALY. PRP versus corticosteroid injections provided a NMB measured by VAS: $428 941.12 versus $375 788.21, BCTQ-S: $417 115.09 versus $356 614.18, and BCTQ-F: $421 706.44 versus $376 908.45. From a societal perspective, compared to PRP injections, the ICER for corticosteroid injections measured by VAS: -$1024.40/QALY, BCTQ-S: -$899.95/QALY, and BCTQ-F: -$1215.51/QALY. PRP versus corticosteroid injections provided a NMB measured by VAS: $428 171.63 versus $373 944.39, BCTQ-S: $416 345.61 versus $354 770.36, and BCTQ-F: $420 936.95 versus $375 064.63. Conclusions: PRP injections were more cost-effective than methylprednisolone/triamcinolone injections from healthcare and societal perspectives for mild-to-moderate CTS.
- 22 May 2022
- Published by SAGE Publications in HAND
- Vol. 19 (1) , 113-127
Platelet-Rich Plasma Versus Corticosteroid Injections for the Treatment of Mild-to-Moderate Carpal Tunnel Syndrome: A Markov Cost-Effectiveness Decision Analysis
Background: Platelet-rich plasma (PRP) or corticosteroid injections may be used to conservatively treat mild-to-moderate carpal tunnel syndrome (CTS). We evaluated the cost-effectiveness of PRP injections versus corticosteroid injections for the treatment of mild-to-moderate CTS. Methods: Markov modeling was used to analyze the base-case 45-year-old patient with mild-to-moderate CTS, unresponsive to conservative treatments, never previously treated with an injection or surgery, treated with a single injection of PRP, or methylprednisolone/triamcinolone 40 mg/mL. Transition probabilities were derived from level-I/II studies, utility values from the Tufts University Cost-Effectiveness Analysis Registry reported using visual analog scale (VAS), Boston Carpal Tunnel Questionnaire Symptom severity (BCTQ-S), and Boston Carpal Tunnel Questionnaire Functional status (BCTQ-F), and costs from Medicare, published studies, and industry. Analyses were performed from healthcare/societal perspectives. Outcomes were incremental cost-effectiveness ratios (ICER) and net monetary benefits (NMB). Willingness-to-pay thresholds were $50 000 and $100 000. Deterministic/probabilistic sensitivity analyses were performed. Results: From a healthcare perspective, compared to PRP injections, the ICER for corticosteroid injections measured by VAS: -$13.52/quality-adjusted-life-years (QALY), BCTQ-S: -$11.88/QALY, and BCTQ-F: -$16.04/QALY. PRP versus corticosteroid injections provided a NMB measured by VAS: $428 941.12 versus $375 788.21, BCTQ-S: $417 115.09 versus $356 614.18, and BCTQ-F: $421 706.44 versus $376 908.45. From a societal perspective, compared to PRP injections, the ICER for corticosteroid injections measured by VAS: -$1024.40/QALY, BCTQ-S: -$899.95/QALY, and BCTQ-F: -$1215.51/QALY. PRP versus corticosteroid injections provided a NMB measured by VAS: $428 171.63 versus $373 944.39, BCTQ-S: $416 345.61 versus $354 770.36, and BCTQ-F: $420 936.95 versus $375 064.63. Conclusions: PRP injections were more cost-effective than methylprednisolone/triamcinolone injections from healthcare and societal perspectives for mild-to-moderate CTS.
- 22 April 2022
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 75 (8) , 2650-2657
Outcomes associated with proton pump inhibitors and distal radius fractures: A post-hoc comparative analysis
- 22 April 2022
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 75 (8) , 2650-2657
Outcomes associated with proton pump inhibitors and distal radius fractures: A post-hoc comparative analysis